Medizinische Klinik A

Klinische Studien

Klinische Studien helfen, die Behandlungsergebnisse stetig weiter zu verbessern. Daher beteiligt sich die Medizinische Klinik A an zahlreichen nationalen und internationalen multizentrischen Studien. Die Therapieoptionen, die wir hierbei anbieten können, sind naturgemäß Behandlungsansätze, die den neuesten Stand des medizinischen Fortschritts darstellen und der Allgemeinheit noch nicht zur Verfügung stehen.
Falls Sie an einer klinischen Studie teilnehmen möchten oder allgemeine Informationen benötigen wenden Sie sich bitte an unsere wissenschaftliche Koordinatorin und Studienmanagerin Claudia Bieber-Tuschen oder an die Ansprechpartnerin des Studienteams der Medizinischen Klinik A, Kerstin Vehring.

Lymphomstudien

DLBCL - Primärtherapie

R-CHOEP–brut
Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma; Eudra CT 2017-003256-22

OPTIMAL>60
Improvement of Outcome and Reduction of Toxicity in Elderly Patients with CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET based Reduction of Therapy in Combination with Vitamin D Substitution; EudraCT 2010-019587-36

DLBCL - Rezidivtherapie

NIVEAU
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxalipatin plus Rituximab in case of CD20+ Disease; EudraCT 2016-002272-27

GOAL
Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma; EudraCT 2014-004780-21

Epizyme
An open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B cell Lyphomas; Eudra-CT 2016-001499-31

ZNS-Lymphom - Primärtherapie

MATRIX/IELSG43
High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma-randomized phase III Trial; EudraCT 2012-000620-17

MARTA
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients; EudraCT 2016-001628-72

Mantelzelllymphom - Primärtherapie

TRIANGLE
Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing induction in generalized matle cell Lymphoma – a European mcl network study; EudraCT 2014-001363-12

ACE-LY-308
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of BR alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma; EudraCT 2015-005220-26

MCL R2 elderly
Efficacy of alternating Immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional Lenalidomide with Rituximab versus Rituximab alone for older patients with mantle cell lymphoma; EudraCT 2012-002542-20

Mantelzelllymphom - Rezidivtherapie

MO39107
A Phase II study exploring the safety and efficacy of Atezolizumab administered in combination with Obnituzumab or Rituximab in patients with relapsed/refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma and Waldenström Macroglobulinemia ; EudraCT 2016-003579-22

Follikuläres Lymphom - Rezidivtherapie

CHRONOS-4
A phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent Non-Hodgkin’s Lymphoma (iNHL); EudraCT 2015-001088-38

Hodgkin Lymphom - Primärtherapie

HD21-Studie
Ein randomisiert-kontrollierter Vergleich von 6 Zyklen BEACOPP eskaliert und 6 Zyklen BrECADD beim fortgeschrittenen Hodgkin Lymphom“ (Phase III, multizentrisch, randomisiert); EudraCT 2014-005130-55

NIVAHL
Nivolumab and AVD in early-stage unfavorable classical Hodgkin-lymphoma; EudraCT 2016-002626-37

Lymphomplasmozytisches Lymphom/ Waldenström - Rezidivtherapie

Parexel
A Phase 3, Randomized, open-Label, Multicenter Study Comparing the Efficacy and Safty of the Bruton´s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström´s Macroglobulinemia; EudraCT 2016-002980-33

Kontakt zum Studienbüro:

Universitätsklinikum Münster
Studienbüro Med. A
Albert-Schweitzer-Campus 1, Gebäude A1
Ebene 11 Ost Raum 11.203
48149 Münster
T 0251 83-49963/45362
F 0251 83-49964